Known targets — ChEMBL curated mechanism
ADRB1CDK4CDK6CHRM2CHRM3DPP4DRD2DRD3DRD4EGFRHRH1HTR1BHTR1DHTR1FHTR2AHTR2CHTR4SLC6A2SLC6A4
The experimentally established mechanism targets of Succinic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.50 |
| ▸ | OR51E2 | Q9H255 | 2/20 | 0.77 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.77 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.77 |
| ▸ | GABRR1 | P24046 | 2/20 | 0.71 |
| ▸ | LMNA | P02545 | 6/20 | 0.69 |
| ▸ | EGLN1 | Q9GZT9 | 5/20 | 0.69 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.69 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.69 |
| ▸ | TSHR | P16473 | 3/20 | 0.56 |
| ▸ | THRB | P10828 | 2/20 | 0.56 |
| ▸ | BLM | P54132 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.56 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.56 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.56 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.56 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.56 |
| ▸ | GABRR3 | A8MPY1 | 1/20 | 0.56 |
| ▸ | GABRP | O00591 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Succinic Acid SCHEMBL6597777 | 1.00 | OR51E2 (0.77) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Succinic Acid SCHEMBL28253757 | 0.96 | OR51E2 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Succinic Acid SCHEMBL28253755 | 0.96 | OR51E2 (0.71) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL2116443 | 0.88 | — | — | |
| Glycine SCHEMBL391786 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL3640989 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL93765 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL6675874 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1LMNA | |
| Glycine SCHEMBL30070584 | 0.88 | — | — | |
| Glycine SCHEMBL391027 | 0.88 | GLRA1 (1.00) | OR51E2GLRA1SLC6A9GABRR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-108203254-A | Concrete composite foaming agent | 大连理工大学 | 2018-06-26 | — | — | CN | claimed |
| CN-108203312-A | Light foamed concrete | 大连理工大学 | 2018-06-26 | — | — | CN | claimed |
| CN-105523833-A | Special slow release water-soluble fertilizer for cotton, and preparation method thereof | CHENGDU NEW KELI CHEM SCI CO | 2016-04-27 | — | — | CN | claimed |
| CN-104557298-A | Special sustained-release water-soluble fertilizer for potatoes and preparation method of fertilizer | CHENGDU NEW KELI CHEM SCI CO | 2015-04-29 | — | — | CN | claimed |
| US-20120093814-A1 | Fusion Proteins Comprising Canine FC Portions | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-04-19 | — | — | US | claimed |
| EP-2413969-A2 | FUSION PROTEINS COMPRISING CANINE FC PORTIONS | Boehringer Ingelheim International GmbH (DE) | 2012-02-08 | — | — | EP | claimed |
| CN-101993370-A | Glaucocalyxin A acid ester derivative as well as preparation method and application of Glaucocalyxin A acid ester derivative | SHANGHAI JINHAO PHARMACEUTICAL DEV CO LTD | 2011-03-30 | — | — | CN | claimed |
| WO-2010117760-A2 | FUSION PROTEINS COMPRISING CANINE FC PORTIONS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2010-10-14 | — | — | WO | claimed |
| EP-2162464-A1 | NATRIURETIC FUSION PROTEINS | Boehringer Ingelheim International GmbH (DE) | 2010-03-17 | — | — | EP | claimed |
| WO-2008154226-A1 | NATRIURETIC FUSION PROTEINS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | claimed |
| US-20260027206-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20260027204-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2026-01-29 | — | — | US | disclosed |
| US-20230321234-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-10-12 | — | — | US | disclosed |
| US-20230263887-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | MERCK SHARP & DOHME LLC (US) | 2023-08-24 | — | — | US | disclosed |
| US-11633476-B2 | Stable formulations of programmed death receptor 1 (PD-1) antibodies and methods of use thereof | MERCK SHARP & DOHME LLC (US) | 2023-04-25 | — | — | US | disclosed |
| US-20100179181-A1 | PHARMACEUTICAL FORMULATIONS OF BIODEGRADABLE BIOCOMPATIBLE CAMPTOTHECIN-POLYMER CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2010-07-15 | — | — | US | disclosed |
| WO-2010068759-A1 | PHARMACEUTICAL FORMULATIONS OF BIODEGRADABLE BIOCOMPATIBLE CAMPTOTHECIN-POLYMER CONJUGATES | MERSANA THERAPEUTICS, INC. (US) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010053596-A1 | BISPECIFIC INTRACELLULAR DELIVERY VEHICLES | UNIVERSITY OF WASHINGTON (US) | 2010-05-14 | — | — | WO | disclosed |
| EP-2162464-A1 | NATRIURETIC FUSION PROTEINS | Boehringer Ingelheim International GmbH (DE) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008154226-A1 | NATRIURETIC FUSION PROTEINS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260027206-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | PDCD1, CD274, PDCD10 | SLC6A2 1294/4885OR51E2 2686/4885GLRA1 299/4885 |
| US-20120093814-A1 | Fusion Proteins Comprising Canine FC Portions | FCGRT, FCGR3B, FCGR2A | SLC6A2 4422/4885OR51E2 2395/4885GLRA1 2724/4885 |
| US-20100179181-A1 | PHARMACEUTICAL FORMULATIONS OF BIODEGRADABLE BIOCOMPATIBLE CAMPTOTHECIN-POLYMER CONJUGATES | PAICS, TK1, PKLR | SLC6A2 2226/4885OR51E2 3591/4885GLRA1 3960/4885 |
| US-20260027204-A1 | STABLE FORMULATIONS OF PROGRAMMED DEATH RECEPTOR 1 (PD-1) ANTIBODIES AND METHODS OF USE THEREOF | PDCD1, CD274, PDCD10 | SLC6A2 1292/4885OR51E2 2681/4885GLRA1 298/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.